Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) gives an update on top-line data’s oral presentation from Phase III SUNRISE Trial of Bavituximab at the European Society for Medical Oncology (ESMO) 2016 Congress.
Oral Presentation of Phase III SUNRISE Trial of Bavituximab
Peregrine Pharmaceuticals has announced today that top line data from the third phase SUNRISE trial of bavituximab will be given as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The Phase III SUNRISE trial of bavituximab involves patients that have been previously treated locally, with metastatic or advanced non-squamous non-small cell lung cancer (NSCLC).
The data presented includes a biomarker in the SUNRISE trial, which was mutually related with a statistically compelling improvement in the long-term survival for those patients who have been treated with bavituximab in conjunction with docetaxel. This was later compared to patients who are treated with docetaxel only.
Peregrine Pharmaceuticals will enter a new patent application pertaining to the use of the biomarker before the presentation of the results at the ESMO 2016 Congress held in Copenhagen, Denmark on October 7 to 11, 2016.
Peregrine’s Clinical Development Strategy for Bavituximab
Bavituximab is an investigational chimeric monoclonal antibody that targets phosphatidylserine (PS). The phosphatidylserine (PS), which targets antibodies have been demonstrated to shift the behavior of immune cells in tumors, this results in multiple signs of anti-tumor immune responses and immune activation.
Peregrine Pharmaceutical’s clinical development blueprint for bavituximab is currently fixated on tiny, curable proof-of-concept trials classifying the drug in combination with other options for the treatment of cancer. The intention concerning this strategy is to manage funds for development and research while sustaining the generation of clinical data. This is to further validate and give a boost to bavituximab’s combination potential which will be a very important matter in getting a partner to help further innovate the program.